A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...

The disease is characterized by progressive motor, cognitive, and psychiatric decline. Three treatments are approved to treat ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

Huntington’s disease poses a threat to the brain—the core governing system of sensation, intellectual ability, nerve-related ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...

Huntington's Disease is one of the most devastating diseases out there and many people have never heard of it. Actor WIll ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...